126 related articles for article (PubMed ID: 38646639)
1. IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis.
Vadevoo SMP; Kang Y; Gunassekaran GR; Lee SM; Park MS; Jo DG; Kim SK; Lee H; Kim WJ; Lee B
Theranostics; 2024; 14(6):2605-2621. PubMed ID: 38646639
[No Abstract] [Full Text] [Related]
2. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages.
Gunassekaran GR; Poongkavithai Vadevoo SM; Baek MC; Lee B
Biomaterials; 2021 Nov; 278():121137. PubMed ID: 34560422
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.
Wanderley CW; Colón DF; Luiz JPM; Oliveira FF; Viacava PR; Leite CA; Pereira JA; Silva CM; Silva CR; Silva RL; Speck-Hernandez CA; Mota JM; Alves-Filho JC; Lima-Junior RC; Cunha TM; Cunha FQ
Cancer Res; 2018 Oct; 78(20):5891-5900. PubMed ID: 30104241
[TBL] [Abstract][Full Text] [Related]
4. IL4 Receptor-Targeted Proapoptotic Peptide Blocks Tumor Growth and Metastasis by Enhancing Antitumor Immunity.
Vadevoo SMP; Kim JE; Gunassekaran GR; Jung HK; Chi L; Kim DE; Lee SH; Im SH; Lee B
Mol Cancer Ther; 2017 Dec; 16(12):2803-2816. PubMed ID: 28878029
[TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV antagonizes M2 phenotype macrophage polarization-evoked ovarian cancer cell malignant progression by suppressing the HMGB1-TLR4 axis.
Wang X; Gao S; Song L; Liu M; Sun Z; Liu J
Mol Immunol; 2021 Feb; 130():113-121. PubMed ID: 33308900
[TBL] [Abstract][Full Text] [Related]
6. Role of scavenger receptors as damage-associated molecular pattern receptors in Toll-like receptor activation.
Komai K; Shichita T; Ito M; Kanamori M; Chikuma S; Yoshimura A
Int Immunol; 2017 Feb; 29(2):59-70. PubMed ID: 28338748
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2/NOX2/autophagy axis.
Shiau DJ; Kuo WT; Davuluri GVN; Shieh CC; Tsai PJ; Chen CC; Lin YS; Wu YZ; Hsiao YP; Chang CP
Sci Rep; 2020 Aug; 10(1):13582. PubMed ID: 32788720
[TBL] [Abstract][Full Text] [Related]
8. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
9. MALAT1 shuttled by extracellular vesicles promotes M1 polarization of macrophages to induce acute pancreatitis via miR-181a-5p/HMGB1 axis.
Liu J; Niu Z; Zhang R; Peng Z; Wang L; Liu Z; Gao Y; Pei H; Pan L
J Cell Mol Med; 2021 Oct; 25(19):9241-9254. PubMed ID: 34448533
[TBL] [Abstract][Full Text] [Related]
10. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
[TBL] [Abstract][Full Text] [Related]
11. HMGB1 Facilitated Macrophage Reprogramming towards a Proinflammatory M1-like Phenotype in Experimental Autoimmune Myocarditis Development.
Su Z; Zhang P; Yu Y; Lu H; Liu Y; Ni P; Su X; Wang D; Liu Y; Wang J; Shen H; Xu W; Xu H
Sci Rep; 2016 Feb; 6():21884. PubMed ID: 26899795
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk.
Sekiguchi F; Domoto R; Nakashima K; Yamasoba D; Yamanishi H; Tsubota M; Wake H; Nishibori M; Kawabata A
Neuropharmacology; 2018 Oct; 141():201-213. PubMed ID: 30179591
[TBL] [Abstract][Full Text] [Related]
13. Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression.
Griess B; Mir S; Datta K; Teoh-Fitzgerald M
Free Radic Biol Med; 2020 Feb; 147():48-60. PubMed ID: 31863907
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p.
Vadevoo SMP; Gunassekaran GR; Yoo JD; Kwon TH; Hur K; Chae S; Lee B
Front Immunol; 2022; 13():976196. PubMed ID: 36483544
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism.
Rojas A; Delgado-López F; Perez-Castro R; Gonzalez I; Romero J; Rojas I; Araya P; Añazco C; Morales E; Llanos J
Tumour Biol; 2016 Mar; 37(3):3321-9. PubMed ID: 26440051
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 4 plays a key role in advanced glycation end products-induced M1 macrophage polarization.
Liu Z; Ma Y; Cui Q; Xu J; Tang Z; Wang Y; He C; Wang X
Biochem Biophys Res Commun; 2020 Oct; 531(4):602-608. PubMed ID: 32814631
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy.
Pandya AD; Jäger E; Bagheri Fam S; Höcherl A; Jäger A; Sincari V; Nyström B; Štěpánek P; Skotland T; Sandvig K; Hrubý M; Mælandsmo GM
Int J Nanomedicine; 2019; 14():6269-6285. PubMed ID: 31496685
[TBL] [Abstract][Full Text] [Related]
18. Acceptor Engineering for Optimized ROS Generation Facilitates Reprogramming Macrophages to M1 Phenotype in Photodynamic Immunotherapy.
Yang G; Ni JS; Li Y; Zha M; Tu Y; Li K
Angew Chem Int Ed Engl; 2021 Mar; 60(10):5386-5393. PubMed ID: 33236483
[TBL] [Abstract][Full Text] [Related]
19. A novel chrysin thiazole derivative polarizes macrophages to an M1 phenotype via targeting TLR4.
Feng X; Yu W; Cao L; Meng F; Cong M
Int Immunopharmacol; 2020 Nov; 88():106986. PubMed ID: 33182070
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
